Ravaud 2015.

Study characteristics
Methods	Study type: multicentre RCT Phase: 2 Accrual period: data not found Blinding: open label design Strata: MSKCC risk category IMC: used to analyse tumour responses Crossover: not allowed
Participants	Histology: predominantly clear‐cell mRCC Prior systemic therapy: treatment‐naïve Eligible PS: Karnofsky PS 70% or better Measurable disease: required Non metastatic %: 0, metastatic disease mandatory M/F: 269/96 Age median (range): 60 (20 to 84) Prior nephrectomy: partial or radical nephrectomy mandatory Prognostic strata: system, good/intermediate/poor risk: MSKCC, 131/208/26
Interventions	Everolimus 10 mg po and bevacizumab 10mg/kg iv every 2 wks vs IFN 9 MIU 3 times per wk plus bevacizumab 10 mg/kg every 2 weeks
Outcomes	PFS: primary endpoint OS: secondary outcome AE: secondary outcome, reported in toxicity table QoL: not assessed RR: secondary outcome Other: duration of response
Funding Sources	Industry sponsored
Declarations of interest	Reported
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"randomized 1:1"
Allocation concealment (selection bias)	Unclear risk	Data not found
Blinding of participants and personnel (performance bias) Objective outcomes	Low risk	"open‐label, phase II RECORD‐2 trial"; personnel and participants were not blinded to treatment, different drug administration forms used, no effect on OS expected
Blinding of participants and personnel (performance bias) Subjective outcomes	Unclear risk	"open‐label, phase II RECORD‐2 trial"; personnel and participants were not blinded to treatment, different drug administration forms used
Blinding of outcome assessment (detection bias) Objective outcomes	Low risk	Tumor response and progression were evaluated by the local radiologist and independent central review
Blinding of outcome assessment (detection bias) Subjective outcomes	High risk	Tumor response and progression were evaluated by the local radiologist and independent central review; trial design is open‐label
Incomplete outcome data (attrition bias) PFS, OS	Low risk	ITT population reported, 3 patients did not receive treatment
Incomplete outcome data (attrition bias) Response rate	Low risk	ITT population reported, 3 patients did not receive treatment
Incomplete outcome data (attrition bias) Serious and minor adverse events	Low risk	All but 1 participant who received treatment were included in safety analysis
Incomplete outcome data (attrition bias) Quality of life	Unclear risk	No available data
Selective reporting (reporting bias)	Low risk	All outcomes reported
Other bias	Unclear risk	Study not powered to show significant treatment effect